Table 3.
Comparison of RAS-positive and BRAF-positive papillary thyroid cancers
| Mutation | Positive predictive value (test specificity) | Tumor size (cm) | Histological subtype | Lymphovascular invasion | Extrathyroidal extension | Lymph node metastases |
|---|---|---|---|---|---|---|
| RAS-positive cancers (n = 8) | 47 % (97.3 %) | Range: 1.0–3.6 Median: 1.9 | 8 – follicular variant PTC | 0/8 (0 %) | 0/8 (0 %) | 0/8 (0 %) |
| BRAF-positive cancers (n = 8a) | 100 % (100 %) | Range: 1.0–4.8 Median: 1.4 | 6 – classical variant PTCb 1 – tall cell variant PTC 1 – follicular variant PTC | 5/8 (62.5 %) | 1/8 (12.5 %) | 1/8 (12.5 %) |
aNine BRAF mutations were detected in the cohort. However, one patient did not pursue surgery because of other medical conditions. Therefore eight BRAF-positive cases are shown; bincluding two classical variant PTCs with tall cell features. PTC, papillary thyroid carcinoma